Results 81 to 90 of about 22,974 (229)

Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone [PDF]

, 2022
Miranda Greiner, Matisyahu Shulman, Jennifer Scodes, Tse‐Hwei Choo, Martina Pavlicová, Onumara Opara, Aimee Campbell, Patricia Novo, Marc Fishman, Joshua D. Lee, John Rotrosen, Edward V. Nunes   +11 more
openalex   +1 more source

Efficacy of Weight‐Lowering Agents on Fat Distribution: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

Obesity Reviews, EarlyView.
ABSTRACT Background Pharmacotherapy offers a potential solution for individuals with overweight and obesity to decrease their body weight. However, there is limited knowledge of the effects of antiobesity agents on the distribution of body fat. Methods The PubMed, Embase, and Cochrane Library databases were reviewed for randomized controlled trials ...
Xiuqi Qiao, Weihao Wang, Jiaming Cao, Lixin Guo, Qi Pan   +4 more
wiley   +1 more source

Clinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients with Severe Pruritus [PDF]

, 2016
Jungsoo Lee, Jung U Shin, Seongmin Noh, Chang Ook Park, Kwang Hoon Lee   +4 more
openalex   +1 more source

Disparities in Naltrexone Prescriptions to Medicaid Enrollees During the COVID-19 Pandemic [PDF]

, 2022
Hemmy A. Subervi, Lysine E. Varghese, Brian J. Piper   +2 more
openalex   +1 more source

Expanding Access to Opioid Use Disorder Treatment: Low‐Threshold Buprenorphine Dispensing via an Interprofessional Mobile Medical Unit in Chicago

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 2, February 2026.
ABSTRACT Background Less than 25% of individuals with opioid use disorder access medication treatment. Lower income and segregated Black and Hispanic communities often have little to no access to services. In 2021, the Drug Enforcement Administration authorized opioid treatment programs to add mobile units to their licensure, extending treatment to ...
Abigail T. Elmes‐Patel, Jennie B. Jarrett, Antonio D. Jimenez, Stockton M. Mayer, Sarah E. Messmer   +4 more
wiley   +1 more source

Pharmacological MRI: Utility in Understanding Drug Mechanisms in Psychiatric Disorders

Journal of Magnetic Resonance Imaging, Volume 63, Issue 2, Page 346-363, February 2026.
ABSTRACT Pharmacological MRI (pharmaMRI) has emerged as a powerful tool to study how psychoactive drugs affect brain function and to uncover mechanisms of drug action in psychiatric disorders. This review provides an overview of key techniques used in pharmaMRI, including BOLD‐fMRI, arterial spin labeling (ASL), and cerebral blood volume (CBV) mapping,
Christin Y. Sander, Tudor M. Ionescu, Mitul A. Mehta, Ottavia Dipasquale, Anouk Schrantee   +4 more
wiley   +1 more source

Naltrexone Induced Agitation Management: Employing a Hybrid Artificial Neural Network Model to Determine the Appropriate Dosage of Intravenous Diazepam

Namık Kemal Tıp Dergisi
Aim: Agitation is a prevalent symptom of opioid withdrawal caused by naltrexone. Managing agitation induced by naltrexone poses challenges as current drug interventions are either ineffective or require intensive care.
Seyed Ali MOHTARAMI, Sayed Masoud HOSSEINI, Shahin SHADNIA, Babak MOSTAFAZADEH, Peyman Erfan Talab EVINI, Omid MEHRPOUR, Shakiba FARHADPUR, Mitra RAHIMI   +7 more
doaj   +1 more source

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo, Hui Liu, Yu‐Jing Song, Jian‐Hua Wang, Danfeng Liu, Zhi‐Wei Zheng, Jia‐Jun Li, Boya Li, An Song, Wei He, Lei‐Lei Yang, Shuo Wang   +11 more
wiley   +1 more source

Approaches to the Development of a Low-dose Naltrexone Preparation in the Form of a Nasal Spray (Review)

, 2021
Yu. M. Domnina, В. В. Суслов, С. А. Кедик, P. O. Volkova   +3 more
openalex   +2 more sources

Circulating levels of proglucagon‐derived peptides are differentially regulated by the glucagon‐like peptide‐1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6‐month long interventional study [PDF]

, 2023
Konstantinos Stefanakis, Alexander Kokkinos, Georgia Argyrakopoulou, Sofia Konstantinidou, Stamatia Simati, Matina Kouvari, Ajay Kumar, Bhanu Kalra, Melina Kumar, Nikolaos Bontozoglou, Konstantina Kyriakopoulou, Christos S. Mantzoros   +11 more
openalex   +1 more source